BROOKS.NS
Brooks Laboratories Limited [BROOKS.NS] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
BROOKS.NS Stock Summary
Top 10 Correlated ETFs
BROOKS.NS
Top 10 Correlated Stocks
BROOKS.NS
In the News
BROOKS.NS Financial details
Company Rating
Strong Buy
Market Cap
1.54B
Income
-233.3M
Revenue
789.7M
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
335
Optionable
No
Shortable
Yes
Earnings
10 Aug 2022
P/E
-6.61
Forward P/E
-
PEG
-1.79
P/S
1.95
P/B
1.92
P/C
-
P/FCF
-
Quick Ratio
0.04
Current Ratio
0.89
Debt / Equity
-
LT Debt / Equity
0.1
-
-
EPS (TTM)
-10.74
EPS next Y
-
EPS next Q
-
EPS this Y
-0.28%
EPS next Y
-
EPS next 5Y
-144.06%
EPS last 5Y
1.91%
Revenue last 5Y
10.33%
Revenue Q/Q
-15.36%
EPS Q/Q
-36.36%
-
-
-
-
SMA20
-29.5%
SMA50
-34.22%
SMA100
-38.64%
Inst Own
-
Inst Trans
-
ROA
-11%
ROE
-33%
ROC
-0.26%
Gross Margin
23%
Oper. Margin
-49%
Profit Margin
-30%
Payout
-
Shs Outstand
24.7M
Shs Float
7M
-
-
-
-
Target Price
-
52W Range
57.9-143.45
52W High
-56.19%
52W Low
+9.91%
RSI
29.65
Rel Volume
0.54
Avg Volume
44.97K
Volume
24.22K
Perf Week
-2.03%
Perf Month
-36.62%
Perf Quarter
-44.7%
Perf Half Y
-41.8%
-
-
-
-
Beta
1.45352
-
-
Volatility
3.72%, 13.59%
Prev Close
-1.1%
Price
62.65
Change
-1.1%
BROOKS.NS Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-03-31
| Metric | History | 2018-03-31 | 2019-03-31 | 2020-03-31 | 2021-03-31 | 2022-03-31 |
|---|---|---|---|---|---|---|
| Revenue per share | 28.7 | 28.35 | 39.26 | 31.2 | 36.87 | |
| Net income per share | -7.12 | -7.63 | -13.84 | -7.84 | -7.82 | |
| Operating cash flow per share | -3.18 | -2.6 | -5.33 | 1.8 | -15.16 | |
| Free cash flow per share | -6.14 | -3.05 | -6.8 | -0.47 | -26.33 | |
| Cash per share | 0.5 | 1.28 | 0.22 | 0.87 | 2.1 | |
| Book value per share | 58.97 | 54.17 | 55.88 | 32.04 | 25.52 | |
| Tangible book value per share | 58.97 | 53.98 | 55.73 | 31.76 | 54.12 | |
| Share holders equity per share | 58.97 | 54.17 | 55.88 | 32.04 | 25.52 | |
| Interest debt per share | 15.65 | 17.59 | 17.6 | 13.96 | 11.48 | |
| Market cap | 1.34B | 954.96M | 268.56M | 1.51B | 1.8B | |
| Enterprise value | 1.61B | 1.24B | 540.97M | 1.82B | 2.03B | |
| P/E ratio | -9.67 | -6.45 | -1.1 | -7.82 | -9.32 | |
| Price to sales ratio | 2.4 | 1.74 | 0.39 | 1.96 | 1.98 | |
| POCF ratio | -21.61 | -18.91 | -2.86 | 33.96 | -4.81 | |
| PFCF ratio | -11.21 | -16.14 | -2.24 | -131.11 | -2.77 | |
| P/B Ratio | 1.17 | 0.91 | 0.27 | 1.91 | 2.86 | |
| PTB ratio | 1.17 | 0.91 | 0.27 | 1.91 | 2.86 | |
| EV to sales | 2.89 | 2.26 | 0.78 | 2.36 | 2.23 | |
| Enterprise value over EBITDA | -18.53 | -22.64 | -15.39 | 145.73 | -15.07 | |
| EV to operating cash flow | -26.03 | -24.59 | -5.76 | 40.8 | -5.41 | |
| EV to free cash flow | -13.51 | -20.99 | -4.52 | -157.52 | -3.12 | |
| Earnings yield | -0.1 | -0.16 | -0.91 | -0.13 | -0.11 | |
| Free cash flow yield | -0.09 | -0.06 | -0.45 | -0.01 | -0.36 | |
| Debt to equity | 0.51 | 0.6 | 0.6 | 1.05 | 0.98 | |
| Debt to assets | 0.34 | 0.37 | 0.38 | 0.51 | 0.31 | |
| Net debt to EBITDA | -3.15 | -5.23 | -7.75 | 24.43 | -1.68 | |
| Current ratio | 0.74 | 0.67 | 0.83 | 0.75 | 1.25 | |
| Interest coverage | -6.38 | -4.09 | -2.76 | -2.13 | -7.01 | |
| Income quality | 0.45 | 0.34 | 0.39 | -0.23 | 1.94 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0.07 | 0.08 | 0.06 | 0.09 | 0 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0.93 | 0.17 | 0.28 | -1.26 | 0.74 | |
| Capex to revenue | -0.1 | -0.02 | -0.04 | -0.07 | -0.3 | |
| Capex to depreciation | -0.89 | -0.13 | -0.39 | -0.79 | -3.76 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 97.17 | 96.41 | 131.93 | 75.2 | 67.01 | |
| ROIC | -0.08 | -0.09 | -0.13 | -0.11 | -0.11 | |
| Return on tangible assets | -0.08 | -0.09 | -0.15 | -0.12 | -0.1 | |
| Graham Net | -26.54 | -28.48 | -29.62 | -27.93 | -17.27 | |
| Working capital | -102.02M | -154.98M | -78.81M | -159.13M | 123.04M | |
| Tangible asset value | 1.14B | 1.05B | 981.36M | 784.6M | 1.34B | |
| Net current asset value | -285.44M | -308.38M | -215.3M | -351.28M | -4.08M | |
| Invested capital | 0.24 | 0.3 | 0.28 | 0.4 | 0.4 | |
| Average receivables | 0 | 0 | 0 | 0 | 0 | |
| Average payables | 224.3M | 268.17M | 266.03M | 285.1M | 294.77M | |
| Average inventory | 95.54M | 107.31M | 119.14M | 186.89M | 255.63M | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 207.17 | 217.96 | 177.91 | 204.52 | 162.77 | |
| Days of inventory on hand | 89.21 | 80.74 | 94.02 | 155.96 | 159.99 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
| Payables turnover | 1.76 | 1.67 | 2.05 | 1.78 | 2.24 | |
| Inventory turnover | 4.09 | 4.52 | 3.88 | 2.34 | 2.28 | |
| ROE | -0.12 | -0.14 | -0.25 | -0.24 | -0.31 | |
| Capex per share | -2.95 | -0.45 | -1.47 | -2.27 | -11.18 |
Quarterly Fundamentals Overview
Last date of statement is 2022-12-31 for Q3
| Metric | History | 2021-12-31 | 2022-03-31 | 2022-06-30 | 2022-09-30 | 2022-12-31 |
|---|---|---|---|---|---|---|
| Revenue per share | 7.7 | 11.53 | 6.93 | 7.32 | 6.19 | |
| Net income per share | -3.14 | -2.72 | -2.79 | -1.9 | -2.03 | |
| Operating cash flow per share | 0 | 0 | 0 | 0 | 0 | |
| Free cash flow per share | 0 | 0 | 0 | 0 | 0 | |
| Cash per share | 0 | 2.1 | 0 | 0.99 | 0 | |
| Book value per share | 0 | 25.53 | 0 | 32.47 | 0 | |
| Tangible book value per share | 0 | 54.14 | 0 | 54.43 | 0 | |
| Share holders equity per share | 0 | 25.53 | 0 | 32.47 | 0 | |
| Interest debt per share | 0 | 10.57 | 0 | 9.77 | 0 | |
| Market cap | 2.48B | 1.8B | 2.14B | 2.68B | 2.7B | |
| Enterprise value | 0 | 2.03B | 0 | 2.92B | 0 | |
| P/E ratio | -7.99 | -6.69 | -7.75 | -14.32 | -13.46 | |
| Price to sales ratio | 13.04 | 6.32 | 12.49 | 14.84 | 17.66 | |
| POCF ratio | 0 | 0 | 0 | 0 | 0 | |
| PFCF ratio | 0 | 0 | 0 | 0 | 0 | |
| P/B Ratio | 0 | 2.86 | 0 | 3.34 | 0 | |
| PTB ratio | 0 | 2.86 | 0 | 3.34 | 0 | |
| EV to sales | 0 | 7.12 | 0 | 16.13 | 0 | |
| Enterprise value over EBITDA | 0 | -44.85 | 0 | -51.82 | 0 | |
| EV to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
| EV to free cash flow | 0 | 0 | 0 | 0 | 0 | |
| Earnings yield | -0.03 | -0.04 | -0.03 | -0.02 | -0.02 | |
| Free cash flow yield | 0 | 0 | 0 | 0 | 0 | |
| Debt to equity | 0 | 0.98 | 0 | 0.88 | 0 | |
| Debt to assets | 0 | 0.31 | 0 | 0.34 | 0 | |
| Net debt to EBITDA | 0 | -5.01 | 0 | -4.16 | 0 | |
| Current ratio | 0 | 1.25 | 0 | 0.89 | 0 | |
| Interest coverage | -11.15 | -6.96 | -16.99 | -18.31 | -14.56 | |
| Income quality | 0 | 0 | 0 | 0 | 0 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0 | 0 | 0 | 0.02 | 0 | |
| Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
| Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
| Capex to depreciation | 0 | 0 | 0 | 0 | 0 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 0 | 39.56 | 0 | 37.21 | 0 | |
| ROIC | 0 | -0.03 | 0 | -0.04 | 0 | |
| Return on tangible assets | 0 | -0.03 | 0 | -0.02 | 0 | |
| Graham Net | 0 | -17.27 | 0 | -23.32 | 0 | |
| Working capital | 0 | 123.04M | 0 | -64.41M | 0 | |
| Tangible asset value | 0 | 1.34B | 0 | 1.34B | 0 | |
| Net current asset value | 0 | -4.08M | 0 | -173.46M | 0 | |
| Invested capital | 0 | 0.4 | 0 | 0.29 | 0 | |
| Average receivables | 0 | 0 | 0 | 0 | 0 | |
| Average payables | 0 | 0 | 0 | 0 | 0 | |
| Average inventory | 0 | 0 | 0 | 0 | 0 | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 0 | 134.44 | 0 | 227.95 | 0 | |
| Days of inventory on hand | 0 | 132.14 | 0 | 133.69 | 0 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
| Payables turnover | 0 | 0.67 | 0 | 0.39 | 0 | |
| Inventory turnover | 0 | 0.68 | 0 | 0.67 | 0 | |
| ROE | 0 | -0.11 | 0 | -0.06 | 0 | |
| Capex per share | 0 | 0 | 0 | 0 | 0 |
BROOKS.NS Frequently Asked Questions
What is Brooks Laboratories Limited stock symbol ?
Brooks Laboratories Limited is a IN stock and trading under the symbol BROOKS.NS
What is Brooks Laboratories Limited stock quote today ?
Brooks Laboratories Limited stock price is $62.65 today.
Is Brooks Laboratories Limited stock public?
Yes, Brooks Laboratories Limited is a publicly traded company.
Company Profile
- Volume Average 44.97K
- Market Capitalization 1.54B
- Employee 335
- CEO Mr. Prashant Rathi
- Headquarters Mumbai,IN
- IPO Date 2011-09-02
-
Website
https://www.brookslabs.net 
Brooks Laboratories Limited manufactures and sells pharmaceuticals on contract basis in India and internationally. It offers carbapenem drugs; tablets; dry syrup; liquid and dry power injections; and eye and ear drop. Brooks Laboratories Limited was incorporated in 2002 and is based in Mumbai, India.
